The current financial score of IGC Pharma Inc is 5.36. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 317.00K, representing a year-over-year decrease of 3.94%, while its net profit experienced a year-over-year decrease of 100.67%.
The current valuation score of IGC Pharma Inc is 6.56. Its current P/E ratio is 44.90, which is 16.78% below the recent high of 52.43 and 116.75% above the recent low of -7.52.
The current earnings forecast score of IGC Pharma Inc is 8.00. The average price target is 4.00, with a high of 5.00 and a low of 3.00.
The current price momentum score of IGC Pharma Inc is 4.45. Currently, the stock price is trading between the resistance level at 0.33 and the support level at 0.25, making it suitable for range-bound swing trading.
The current institutional shareholding score of IGC Pharma Inc is 3.00. The latest institutional shareholding proportion is 22.76%, representing a quarter-over-quarter increase of 12.95%.
The current risk assessment score of IGC Pharma Inc is 3.75. The company's beta value is 0.47. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.